Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease

Hiroyuki Sugiura; Nobuo Sezaki; Tatsunori Ishikawa; Taiga Kuroi; Sachiyo Okamoto; Naho Nomura; Taro Masunari; Yukio Nakasako; Toru Kiguchi; Mitsune Tanimoto

doi:10.1002/ccr3.5735

Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease

Clin Case Rep. 2022 Apr 14;10(4):e05735. doi: 10.1002/ccr3.5735. eCollection 2022 Apr.

Authors

Affiliations

¹ Department of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
² Department of Diabetology and Nephrology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
³ Department of Diabetes Endocrinology and Hematology Dokkyo Medical University Saitama Medical Center Koshigaya Japan.

Abstract

Venetoclax is a promising new drug for relapsed or refractory chronic lymphocytic leukemia (CLL). However, venetoclax use had not been reported in severe chronic kidney disease (CKD) patients. We report the first case of relapsed CLL in a severe CKD patient that was successfully treated with venetoclax.

Keywords: chronic lymphocytic leukemia; severe chronic kidney disease; tumor lysis syndrome; venetoclax.

Publication types

Case Reports